Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of the comorbid seizure/epilepsy on the health related quality of life in people with multiple sclerosis: an international multicentric study.
Drulovic J, Pekmezovic T, Tamas O, Adamec I, Aleksic D, Andabaka M, Basic Kes V, Butkovic Soldo S, Cukic M, Despinic L, Dincic E, Djelilovic Vranic J, Grgic S, Habek M, Hristova SI, Ivanovic J, Jovanovic A, Jovicevic V, Krbot Skoric M, Kuzmanovski I, Maric G, Mesaros S, Milanov IG, Miletic Drakulic S, Sinanovic O, Skarpa Prpic I, Sremec J, Tadic D, Toncev G, Sokic D. Drulovic J, et al. Among authors: dincic e. Front Immunol. 2023 Nov 7;14:1284031. doi: 10.3389/fimmu.2023.1284031. eCollection 2023. Front Immunol. 2023. PMID: 38022568 Free PMC article.
Aquaporin4-IgG seropositivity significantly increases the risk of comorbid autoimmune diseases in NMOSD patients: population-based registry data.
Pekmezovic T, Jovicevic V, Andabaka M, Momcilovic N, Veselinovic N, Tamas O, Budmkic M, Todorovic S, Jeremic M, Dincic E, Vojinovic S, Andrejevic S, Mesaros S, Drulovic J. Pekmezovic T, et al. Among authors: dincic e. J Neurol. 2024 Dec;271(12):7525-7536. doi: 10.1007/s00415-024-12698-2. Epub 2024 Sep 22. J Neurol. 2024. PMID: 39306828
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
53 results